Literature DB >> 11057950

Pathology of the adenoma-carcinoma sequence: from aberrant crypt focus to invasive carcinoma.

O W Cummings1.   

Abstract

The adenoma-carcinoma sequence postulates that colorectal carcinomas arise from precursor lesions, called adenomas. All adenomas contain dysplastic epithelium that arises from mutations in either the adenomatous polyposis coli gene or DNA mismatch repair genes. The earliest lesion detected with dysplasia is the aberrant crypt focus. Over time, as this lesion acquires additional mutations, it evolves into a classic adenomatous polyp. Adenomatous polyps are classified as tubular, tubulovillous, or villous. Generally, as polyps increase in size, the degree of dysplasia worsens, the villous component increases, the number of genetic abnormalities increases, and the likelihood of harboring invasive carcinoma increases. Carcinomas associated with DNA mismatch repair mutations are more likely to be poorly differentiated and incite a host lymphocytic response. These tumors seem to have a better prognosis, stage for stage, than typical colorectal carcinomas.

Entities:  

Mesh:

Year:  2000        PMID: 11057950

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  14 in total

Review 1.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

2.  Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps.

Authors:  Hamzah Abu-Sbeih; Ellie Chen; Osman Ahmed; Niharika Mallepally; Phillip Lum; Wei Qiao; Hun Ju Lee; Robert Bresalier; Lan Sun Wang; Brian Weston; Gottumukkala S Raju; Yinghong Wang
Journal:  Dig Dis Sci       Date:  2019-05-03       Impact factor: 3.199

3.  Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer.

Authors:  G Bermano; V Pagmantidis; N Holloway; S Kadri; N A G Mowat; R S Shiel; J R Arthur; J C Mathers; A K Daly; J Broom; J E Hesketh
Journal:  Genes Nutr       Date:  2007-10-13       Impact factor: 5.523

4.  Incidence of colorectal neoplasms among male pilots.

Authors:  Menachem Moshkowitz; Ohad Toledano; Lior Galazan; Aharon Hallak; Nadir Arber; Erwin Santo
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

5.  Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.

Authors:  John P Maufort; Sybil M Genther Williams; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 6.  Gene therapy in the treatment of intestinal inflammation.

Authors:  Catherine van Montfrans; Anje A te Velde; Sander J H van Deventer; Maria Sol Rodriguez Pena
Journal:  Int J Colorectal Dis       Date:  2003-06-25       Impact factor: 2.571

7.  Improved survival of patients with colon cancer detected by screening colonoscopy.

Authors:  Armin Wiegering; Sabine Ackermann; Johannes Riegel; Ulrich A Dietz; Oliver Götze; Christoph-Thomas Germer; Ingo Klein
Journal:  Int J Colorectal Dis       Date:  2016-01-14       Impact factor: 2.571

8.  Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.

Authors:  Juliana C Santos; Alexandre Funck; Isabelle J L Silva-Fernandes; Silvia H B Rabenhorst; Carlos A R Martinez; Marcelo L Ribeiro
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

9.  Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship?

Authors:  Mary Jones; Peter Helliwell; Colin Pritchard; Joseph Tharakan; Joseph Mathew
Journal:  World J Surg Oncol       Date:  2007-05-12       Impact factor: 2.754

10.  RBP4 and THBS2 are serum biomarkers for diagnosis of colorectal cancer.

Authors:  Weiqiang Fei; Li Chen; Jiaxin Chen; Qinglan Shi; Lumin Zhang; Shuiping Liu; Lingfei Li; Lili Zheng; Xiaotong Hu
Journal:  Oncotarget       Date:  2017-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.